ASCO 2019 round-upWith the American Society of Clinical Oncology (ASCO) conference over for another year, Richard Staines presents a round-up Share XASCO 2019 round-uphttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-round-up/
ASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trialKantar analyst Katie Stockstill discusses the results of phase 3 SOPHIA trial that were presented on the last Share XASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trialhttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/kantar-macrogenics-phase-3-sophia-trial/
ASCO 2019 – phase I data generates hope for the futureSometimes interesting stories from the ASCO conference are the phase I data that generates hope for the future. Share XASCO 2019 – phase I data generates hope for the futurehttps://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/amgen-kras-amg510-phase-i-data/
ASCO 2019 – Enfortumab comes out fighting in bladder cancerAt ASCO 2019, results were presented from the phase II EV-201 trial, which evaluated antibody drug conjugate (ADC) Share XASCO 2019 – Enfortumab comes out fighting in bladder cancerhttps://pharmaphorum.com/video/asco-2019-enfortumab-bladder-cancer/
ASCO 2019 – Kantar highlights a selection of exciting Phase I and Phase II resultsAt ASCO, a lot of attention is given to the results of the large, clinical practices changing phase Share XASCO 2019 – Kantar highlights a selection of exciting Phase I and Phase II resultshttps://pharmaphorum.com/video/asco-2019-results-clinical-practices-changing-phase-iii-studies/
Relax criteria to increase sign-ups to cancer trials, says ASCOOnly 3% of patients with cancer in the US enrol on a clinical trial – and the American Share XRelax criteria to increase sign-ups to cancer trials, says ASCOhttps://pharmaphorum.com/news/relax-criteria-to-increase-sign-ups-to-cancer-trials-says-asco/
Gilead highlights Yescarta survival data in ASCO updateGilead’s Kite subsidiary has reported new data from the main trial for its CAR-T Yescarta, hoping to encourage Share XGilead highlights Yescarta survival data in ASCO updatehttps://pharmaphorum.com/news/gilead-highlights-yescarta-survival-data-in-asco-update/
Sanofi trumpets Darzalex rival isatuximab in refractory myelomaSanofi’s plans for a comeback in cancer have taken a step forward with new data on its anti-CD38 Share XSanofi trumpets Darzalex rival isatuximab in refractory myelomahttps://pharmaphorum.com/news/sanofi-darzalex-rival-isatuximab-refractory-myeloma/
Astellas/Seattle Genetics target advanced bladder cancer with enfortumab vedotinRoche and Merck & Co have got their respective immunotherapies Tecentriq and Keytruda approved in bladder cancer – Share XAstellas/Seattle Genetics target advanced bladder cancer with enfortumab vedotinhttps://pharmaphorum.com/news/astellas-seattle-genetics-target-advanced-bladder-cancer-with-enfortumab-vedotin/